Furthermore, we aim to elucidate whether there is a synergistic effect of IBL-302 and trastuzumab in breast cancer models, including in vitro models of trastuzumab resistance, given the published role of PI3K/AKT/mTOR, and more recently of PIM kinase signalling in trastuzumab resistance [36]. This evidence concerns the gene AKT1 and breast carcinoma.